Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

Vincenzo S. Basile, Mario Masellis, Farideh Badri, Andrew D. Paterson, Herbert Y. Meltzer, Jeffrey A. Lieberman, Steven G. Potkin, Fabio Macciardi, James L. Kennedy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

155 Scopus citations


In 112 schizophrenic patients previously treated with typical neuroleptics, we investigated the putative role of the dopamine D3 receptor gene (DRD3) in tardive dyskinesia (TD). Patients were assessed for TD severity using the Abnormal Involuntary Movement Scale (AIMS) and were subsequently genotyped for the MscI polymorphism that identifies a serine to glycine substitution in DRD3. A modified analysis of covariance model, which incorporated several clinical risk factors for TD, was utilized to detect differences in TD severity among the various genotypic groups. The glycine allele of DRD3 was found to be associated with typical neuroleptic-induced TD (F[2,95] = 8.25, p < .0005). Higher mean AIMS scores were found in patients homozygous for the glycine variant of the DRD3 gene, as compared to both heterozygous and serine homozygous patients. Although replication is necessary, this finding supports a role for the dopamine D3 receptor in the pathogenesis of TD. Copyright (C) 1999 American College of Neuropsychopharmacology.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
Issue number1
StatePublished - Jul 1999


  • DRD3
  • Dopamine
  • Extrapyramidal side effects
  • Genetic association
  • Neuroleptics
  • Pharmacogenetics
  • Receptor binding
  • Risk factor
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health


Dive into the research topics of 'Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia'. Together they form a unique fingerprint.

Cite this